NIPH Clinical Trials Search

VISIVLE study

Basic Information

Recruitment status	Recruiting
Health condition(s) or Problem(s) studied	Hepatocellular carcinoma, intrahepatic cholangiocarcinoma,metastatic liver tumor , etc.
Date of first enrollment	27/04/2026
Target sample size	5
Countries of recruitment
Study type	Interventional
Intervention(s)	Intra-abdominal video during minimally invasive anatomical liver resection will be recorded , and the degree of light reflection associated with vascular contraction and relaxation will be analyzed using image pulse wave extraction technology based on the non-contact vital sensing software.

Outcome(s)

Primary Outcome	Pulse identification Rate of the non-contact vital sensing software Rhythmiru in the preserved liver area after Glissonean dissection.
Secondary Outcome	Pulse wave de-identification rate of rismir in the area to be resected after Gleason dissection. Lismil liver surface pulse wave identification rate before gleason dissection. Intraoperative complications Adverse events within 7 days after surgery

Key inclusion & exclusion criteria

Age minimum	>= 18age old
Age maximum	Not applicable
Gender	Both
Include criteria	(1) Age at the time of consent is older than 18 years old. (2) ECOG performance status (PS) is either 0 or 1. (3)Planned minimally invasive (laparoscopic or robotic-assisted) anatomical liver resection. (4)We plan to use ICG (indocyanine green) for identification of segmental boundaries. (5) Adequate major organ function, with the attending physician deeming the patient suitable for general anesthesia . (6) Written informed consent obtained from the patient after receiving a sufficient explanation of the study prior to enrollment.
Exclude criteria	(1) Patients with a history of iodine hypersensitivity. (2) Patients with a history of hypersensitivity to indocyanine green or any of its components. (3) Patients with a prior history of liver resection. (4) Pregnant or lactating women, or women who may be currently pregnant. (5) Patients with a history of severe hypersensitivity. (6) Patients deemed unsuitable for participation by the attending physician.